Which procedure fits which patient

When a surgeon raises both OATS and AMIC as options for a focal knee cartilage defect, the choice usually comes down to one practical measurement: the size of the lesion.

For defects up to roughly 2 cm², OATS — which transplants cylindrical plugs of the patient's own bone and cartilage from a low-load part of the knee — is generally the preferred option in active adults, with the strongest evidence in patients under 45. A mosaicplasty variant (multiple smaller plugs) can extend that ceiling to approximately 4 cm², though the spaces between plugs introduce some fibrocartilage rather than pure hyaline coverage. Beyond that size, harvesting enough graft material carries meaningful donor-site risk, and AMIC becomes the more practical approach. AMIC augments standard microfracture with a bilayer collagen scaffold — the Gille registry, which followed 57 patients with a mean age of 37.3 years and a mean defect size of 3.4 cm², demonstrated sustained benefit at two years, and later work by Schiavoni Panni et al. extended this to a seven-year follow-up for defects larger than 2 cm².

Importantly, no published randomised controlled trial has directly compared OATS and AMIC head-to-head. The guidance clinicians use today rests on separate evidence streams — registry data, systematic reviews, and defect-size logic — rather than a single comparative study. Both procedures target focal full-thickness lesions, most commonly on the femoral condyle, and neither is appropriate for diffuse or end-stage osteoarthritis.

The repair problem both techniques address

Articular cartilage covers the ends of the femoral condyles and acts as the knee's principal load-absorbing surface. Unlike bone or muscle, it contains no blood vessels. Because healing depends on circulating repair cells delivered through the bloodstream, a full-thickness cartilage defect — classified as ICRS grade III or IV — cannot mount any meaningful repair response on its own. The lesion simply remains.

In practice, this means catching sensations, swelling after activity, and pain under load that tend to persist and, over time, worsen. An untreated focal defect can stress the surrounding cartilage and underlying subchondral bone, gradually expanding the area of damage toward a point where joint-preserving surgery is no longer viable.

Both OATS and AMIC are designed to intervene before that progression occurs. The underlying aim is biological restoration of the defect while the surrounding tissue remains structurally sound — preserving the joint rather than replacing it. This window of opportunity closes as the lesion spreads or the broader joint shows signs of generalised degeneration; patients with osteoarthritis beyond Kellgren–Lawrence grade 2 are typically outside the indication for either restorative procedure.

How OATS works and what it delivers

Think of OATS as filling a pothole by lifting a core of intact road surface from a quieter side street and pressing it into the damaged stretch. Surgically, this means harvesting one or more cylindrical plugs — bone and the overlying native hyaline cartilage intact — from the peripheral femoral condyle, an area that bears comparatively little load during normal walking, and press-fitting them into the prepared defect.

What is transplanted is true hyaline cartilage: the same structured, collagen-rich material that originally covered the condyle. It brings the mechanical stiffness, load distribution, and wear resistance of the original surface — properties that fibrocartilage, the scar-like tissue produced by marrow stimulation alone, cannot fully replicate.

Single-plug OAT suits defects up to around 2 cm². The mosaicplasty variant — multiple smaller plugs arranged in a mosaic pattern — can extend coverage to roughly 4 cm², but the spaces between plugs fill with fibrocartilage rather than hyaline tissue. This is a genuine mechanical trade-off, not a minor detail: the more plugs required, the smaller the proportion of true hyaline coverage across the repair surface.

Donor-site morbidity sets a practical ceiling on how much graft can be taken from any one knee. Harvesting beyond that threshold risks pain and functional symptoms at the collection site, which is why the procedure is not routinely extended to larger defects.

Published evidence supports good medium- and long-term outcomes in well-selected patients. Campbell et al.'s Level IV systematic review of 1,117 patients found OAT associated with significantly higher return-to-sport rates; Pareek et al.'s 2016 systematic review confirmed sustained IKDC and Lysholm score improvements at 10-year follow-up. For return to sport, published data identify age under 25 and lesion size under 2 cm² as the strongest positive predictors. More broadly, relative contraindications — BMI above 40, age over 50, Kellgren–Lawrence grade higher than 2, or a prior marrow-stimulation procedure that may have disrupted the subchondral bone plate — each reduce the likelihood of a good outcome and should be weighed carefully at assessment.

How AMIC works and what it delivers

AMIC addresses the root cause of microfracture's limited durability. Standard microfracture perforates the subchondral bone to release marrow stem cells, which form a super-clot across the defect floor. That clot is mechanically fragile — easily disrupted by early joint motion — which is why Kreuz et al. observed significant score deterioration between 18 and 36 months postoperatively, and why Solheim et al. found less than 60% survivorship at three years.

AMIC's addition is a bilayer collagen I/III membrane scaffold — most commonly Chondro-Gide® — cut to fit the prepared defect and fixed over the microfractured bed. The scaffold physically shields the super-clot from disruption and creates a more consistent environment for marrow-derived cells to differentiate and mature. This is the mechanism that separates AMIC from plain microfracture: not a different biology, but a protected version of the same one.

The practical advantage is scalability. Because no graft is harvested from elsewhere in the knee, AMIC is not constrained by donor-site limits. The Gille et al. AMIC Registry enrolled 57 patients with a mean age of 37.3 years and a mean defect size of 3.4 cm² — territory where OAT donor-site morbidity would become a meaningful concern. At one and two years, both VAS pain and functional scores improved significantly (p<0.001). Schiavoni Panni et al. extended follow-up to seven years in defects larger than 2 cm², finding sustained benefit across 21 patients — currently the longest published series for this technique.

The honest limitation is tissue quality. AMIC still produces predominantly fibrocartilage, not the structured hyaline cartilage that OAT transfers directly. Whether the scaffold materially slows fibrocartilage degradation beyond seven years is not yet established. Beck et al.'s sheep model also raised a concern about subchondral bone cyst formation when microfracture is combined with a scaffold — a finding not confirmed at scale in human series, but one worth monitoring on post-operative imaging.

How the outcomes compare

At short-to-medium follow-up, functional outcomes are broadly similar across cartilage repair techniques. Lim et al.'s Level II study comparing microfracture, ACI, and OAT found no statistically significant difference in Lysholm, Tegner, or IKDC scores — genuine equivalence at that time horizon, not a measurement artefact.

The separation becomes visible only when follow-up is extended. OAT's durable advantage for defects at or below 2 cm² is tissue-based: the repair surface is native hyaline cartilage, and the Campbell and Pareek systematic reviews confirmed that return-to-sport rates and functional score gains hold at ten years. No scaffold-augmented technique has an equivalent long-term dataset for this defect size.

For larger defects — beyond the practical reach of OAT's donor-site supply — AMIC's evidence runs to seven years (Schiavoni Panni et al., 21 patients, defects >2 cm²). That is a meaningful horizon, but the repair tissue remains predominantly fibrocartilage, subject in principle to the same durability pressures documented with plain microfracture in earlier studies. Whether the scaffold confers protection beyond seven years is not yet established, and this should be read as an honest evidence gap rather than a clinical failure.

The comparison is further complicated by the absence of a published randomised controlled trial setting OATS directly against AMIC. Each evidence stream is internally coherent — backed by systematic reviews and registry data — but neither has been stress-tested against the other under controlled conditions. Given that limitation, the most defensible clinical conclusion is that defect size drives the choice: OAT for focal lesions within the autograft ceiling, AMIC where that ceiling has been reached. Tissue quality remains the longer-term uncertainty for both.

Recovery, candidacy assessment, and getting advice

Recovery timelines for both procedures are broadly comparable. OATS requires an initial period of protected weight-bearing — typically six weeks — to allow the osteochondral plug to integrate before progressive loading begins; return to sport generally falls within a 6–9 month window. AMIC follows a similar arc, with the critical restriction in the first six to eight weeks protecting the scaffold and maturing super-clot from disruption. Defect size and individual healing response mean the 6–12 month range more accurately reflects the variation seen across published series rather than imprecision in the technique.

A structured pre-operative assessment ties the choice to the individual knee. The imaging workup centres on a weight-bearing radiograph and an MRI with dedicated cartilage sequencing to characterise defect depth, size, and subchondral bone integrity. At Lincolnshire Knee, onMRI™ AI-driven cartilage analysis — including T2 mapping and cartilage volume segmentation — supports that imaging step. Separately, MAI Motion® objective gait assessment can identify load-distribution patterns across the joint that affect both surgical planning and the rehabilitation trajectory after either procedure.

The evidence reviewed here points to a straightforward clinical logic: defect size drives the initial decision, no head-to-head trial has yet resolved the long-term tissue quality question, and both techniques work best when the surrounding joint is sound and the lesion genuinely focal. For patients still uncertain which pathway applies to them, a consultant assessment — not a decision tool — is what converts that uncertainty into a plan.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. Consultations are available at Sleaford NG34 and Grantham NG31 — book an assessment at lincolnshireknee.co.uk.

1. [1] Microfracture surgery. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994